Richard Goodfellow, chief executive officer at Scancell Holdings Plc (LON:SCLP), the developer of novel immunotherapies for the treatment of cancer, talks to Proactive Investors about the “compelling” results from the group's clinical study on a drug for patients suffering from late-stage melanoma.
"These are very powerful data on survival and disease recurrence which are quite unlike, we believe, anything that had previously been seen in other studies," he says.
"We never really expected to be treating patients for so long," he explains. "that is how we discovered patients living up to five years with the disease, which was a surprising finding."
As the group embarks on a clinical trial in the US this year, Goodfellow believes the trial will be successful because "there is tremendous logic to the combination" and says he is "very optimistic" about the study.